Home > Insider Trading > Filing (0001104659-19-069103)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc.	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1493811	Christian Weyer	C/O Intercept Pharmaceuticals, Inc. 10 Hudson Yards, Floor 37 New York NY 10001	Evp, Research & Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-11-27	875	$59.12	16,634	No	4	M	Direct
Common Stock	Acquisiton	2019-11-27	52	$58.74	16,686	No	4	M	Direct
Common Stock	Disposition	2019-11-27	1,040	$101.65	15,646	No	4	S	Direct
Common Stock	Disposition	2019-11-27	357	$109.16	15,289	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	F	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2019-11-27	875	$0.00	875	$59.12
Common Stock	Option to Purchase Common Stock	Disposition	2019-11-27	52	$0.00	52	$58.74

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,108		2027-11-27	No	4	M	Direct
2,937		2028-02-05	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was November 27, 2017.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was January 1, 2018.